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Usha Chakravarthy, PhD, FRCOphth,9 on behalf of the Macular Epiretinal Brachytherapy versus Ranibizumab
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Purpose: To assess the safety and efficacy of epimacular brachytherapy (EMB) for patients with chronic,
active, neovascular age-related macular degeneration (AMD).
Design: Phase 3 randomized controlled trial.
Participants: Patients (n ¼ 363) with neovascular AMD already receiving intravitreal ranibizumab injections.
Intervention: Either pars plana vitrectomy with 24-gray EMB and ongoing pro re nata (PRN) ranibizumab
(n ¼ 224) or ongoing PRN ranibizumab monotherapy (n ¼ 119).
Main Outcome Measures: The coprimary outcomes, at 12 months, were the number of PRN ranibizumab
injections and Early Treatment of Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (VA). Sec-
ondary outcomes included the proportion of participants losing fewer than 15 ETDRS letters, angiographic total
lesion size, choroidal neovascularization (CNV) size, and optical coherence tomography (OCT) foveal thickness. A
predefined subgroup analysis tested the influence of baseline ocular characteristics on the response to EMB.
Results: The mean number of PRN ranibizumab injections was 4.8 in the EMB arm and 4.1 in the ranibizumab
monotherapy arm (P ¼ 0.068). The mean VA change was 4.8 letters in the EMB arm and 0.9 letters in the
ranibizumab arm (95% confidence interval of difference between groups, 6.6 to 1.8 letters). The proportion of
participants losing fewer than 15 letters was 84% in the EMB arm and 92% in the ranibizumab arm (P ¼ 0.007). In
the EMB arm, the mean total lesion size increased by 1.2 mm2 versus 0.4 mm2 in the ranibizumab arm (P ¼ 0.27).
The CNV size decreased by 0.5 mm2 in the EMB arm and by 1.3 mm2 in the ranibizumab arm (P ¼ 0.27). The OCT
foveal thickness decreased by 1.0 mm in the EMB arm and by 15.7 mm in the ranibizumab arm (P ¼ 0.43). Most
subgroups favored ranibizumab monotherapy, some significantly so. One participant showed retinal vascular
abnormality attributed to radiation, but otherwise safety was acceptable.
Conclusions: These results do not support the use of EMB for chronic, active, neovascular AMD. Safety
is acceptable out to 12 months, but radiation retinopathy can occur later, so further follow-up is
planned. Ophthalmology 2016;123:1287-1296 Crown Copyright ª 2016 Published by Elsevier Inc. on behalf of
American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
*Supplemental material is available at www.aaojournal.org.Epimacular brachytherapy (EMB) uses radiation to treat
neovascular age-related macular degeneration (AMD).1
Radiation is known to preferentially damage the proliferating
vascular endothelium and fibroblastic and inflammatory
cells that cause tissue damage in neovascular AMD.2e4 The
EMB devices use a strontium 90 source housed in an endo-
scopic probe. Patients undergo a pars plana vitrectomy, and
then the device is held over the AMD lesion for about 3 to 4
minutes to deliver 24 gray of b radiation. Because of the shortCrown Copyright  2016 Published by Elsevier Inc. on behalf of American Academy
of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).range of strontium b particles in tissue, neighboring structures
such as the optic nerve and lens receive a dose well below the
safety threshold.5 Therefore, EMB has the ability to deliver
radiation directly to the AMD lesion, with stabilized eye
position and with low off-target dosing.
The initial results with EMB were encouraging. An
uncontrolled study of 34 treatment-naïve participants reported
that 91% lost fewer than 15 Early Treatment of Diabetic
Retinopathy (ETDRS) letters over 1 year, despite the fact that1287http://dx.doi.org/10.1016/j.ophtha.2016.02.028
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factor (VEGF) therapy after 2 mandated induction injections
of bevacizumab.1 No cases of radiation retinopathy were
reported. As a result, the Choroidal Neovascularization
(CNV) Secondary to Age-Related Macular Degeneration
Treated with Beta Radiation Epiretinal Therapy (CABER-
NET) study was established to test EMB in a phase 3
randomized controlled trial of treatment-naïve neovascular
AMD.6,7 The study failed to replicate the early results, missing
both its primary visual acuity (VA) end points.6
However, the CABERNET study was not designed to
test whether EMB reduced the demand for anti-VEGF
therapy, or whether it was suitable as a second-line treat-
ment. Specifically, those in the EMB arm received ranibi-
zumab at baseline then monthly pro re nata (PRN), whereas
those in the ranibizumab arm received 3 consecutive
monthly injections from baseline, then quarterly mandated
injections with PRN dosing in the intervening months. Thus,
it was not possible to determine if EMB reduces the demand
for anti-VEGF therapy; moreover, the increased dosing in
the control arm may well have improved the VA in that
group, given that increased dosing may be associated with
better visual outcomes.8 Therefore, it was unknown if EMB
may be suitable as a second-line intervention when used as
an adjunct to anti-VEGF therapy and if it reduces the
demand for anti-VEGF therapy.
The Macular Epiretinal Brachytherapy in Treated Age-
Related Macular Degeneration (MERITAGE) study was a
multicenter phase 2 trial of 53 previously treated patients
who underwent EMB. The trial suggested that EMB may
reduce demand for anti-VEGF therapy with acceptable
visual results out to 1 year.9,10 However, because this study
was not controlled, it was not possible to conclude whether
EMB caused the apparent reduction in anti-VEGF therapy.
We therefore initiated the phase 3 Macular Epiretinal
Brachytherapy versus Ranibizumab (Lucentis) Only Treat-
ment (MERLOT) trial, which was designed to investigate
whether EMB was a safe and efficacious second-line treat-
ment for chronic, active neovascular AMD. Specifically, we
aimed to test the hypothesis that EMB reduces the ongoing
need for anti-VEGF therapy in those who had already
commenced intravitreal injections, while maintaining a
noninferior visual outcome compared with anti-VEGF
monotherapy.
Methods
Study Design
The MERLOT study was an investigator-initiated, multicenter,
phase 3 randomized controlled trial sponsored by a United
Kingdom university hospital. Multicenter research ethics commit-
tee approval was obtained to cover all 24 sites, all participants
provided written informed consent, and the study was conducted in
accordance with the tenets of the Declaration of Helsinki.
Participants
The study enrolled 363 participants with chronic, active neovascular
AMD who were receiving ranibizumab therapy at the time of
screening. Enrollment ran from November 10, 2009, through January128830, 2012. Inclusion criteria included completion of a loading phase of
3 anti-VEGF induction injections, followed by ongoing monthly
PRN therapy, with a minimum of 4 ranibizumab treatments in the
previous 12 months or 2 ranibizumab treatments in the previous 6
months. Exclusion criteria included VAworse than 24 letters (20/80),
prior AMD treatment other than anti-VEGF injections, subfoveal
scarring, known diabetes or features suggesting diabetic retinopathy,
intraocular surgery within the prior 12 weeks, and previous radiation
therapy to the eye, head, or neck (Appendix 2, available at
www.aaojournal.org). If both eyes were eligible, the patient could
elect which eye to treat, in discussion with the clinical investigator,
who should address lens status, clinical response to ranibizumab,
risk factors, VA, visual potential, and other relevant factors.
Randomization and Masking
Participants were randomized in a 2:1 ratio to pars plana vitrec-
tomy and 24-gray EMB with ongoing monthly PRN ranibizumab
(n ¼ 224) or to ongoing monthly PRN ranibizumab monotherapy
(n ¼ 119). Online electronic randomization was undertaken
immediately after eligibility was confirmed by recruiting sites
using a commercial system (MedSciNet, Stockholm, Sweden) and
was stratified by lens status (phakic or pseudophakic) and angio-
graphic lesion type (predominantly classic, minimally classic, or
occult) as determined at the baseline visit. It was not feasible to
mask surgery, but VA testing and macular imaging (which were
the most commonly used criteria to necessitate ranibizumab
retreatment) were undertaken by masked assessors.
Study Treatment
Epimacular brachytherapy could involve either a 20-, 23-, or
25-gauge full pars plana vitrectomy, but the EMB probe (NeoVista,
Freemont, CA) was 20 gauge, and therefore, if necessary, a
smaller-gauge port was enlarged to insert the probe. The EMB
device houses a strontium source in a shielded handpiece (Fig 1,
available at www.aaojournal.org). One end of the handpiece is
connected to a remote handheld actuator by a thin actuator cable.
The other end of the handpiece has a steel, 20-gauge endoprobe
that is inserted into the eye after vitrectomy. The probe is posi-
tioned over the area of greatest disease activity and the actuator is
depressed, causing the strontium source to leave the handpiece and
travel down the probe to near the tip. The probe then is held in
position for the requisite time needed to deliver 24 gray (the exact
time, which is calibrated for each probe, is typically within a range
from 3 to 4 minutes).
Intravitreal 0.5 mg ranibizumab (Lucentis, Novartis, Frimley,
UK) was administered to participants in both study groups using a
monthly PRN dosing regimen if the attending clinical investigator
determined that at least 1 of the following retreatment criteria was
met: a loss of more than 5 ETDRS letters from baseline attributable
to active neovascular AMD; an increase of more than 50 mm in
optical coherence tomography (OCT) central retinal thickness from
the lowest measurement secondary to new or increased subretinal
fluid, intraretinal fluid, or subretinal pigment epithelial fluid; new or
increased subretinal or intraretinal blood; and new neo-
vascularization as confirmed by fluorescein angiography (FA).
Study Examinations, Optical Coherence
Tomography, and Fluorescein Angiography
Participants attended monthly visits with protocol refraction and
testing of best-corrected VA (BCVA) using the ETDRS chart and
methodology, ocular examination, and OCT. Three sites used time-
domain OCT, 14 sites used spectral-domain OCT, and 7 sites used
a mixture of both over the course of the study. Fundus photography
Jackson et al  MERLOT Study of Epimacular Brachytherapyand FA images were obtained at baseline and month 12. All
assessments were performed by masked, trial-certified staff using
certified equipment. Anonymized baseline and month 12 imaging
outputs (color photography, FA, and OCT) were uploaded to a
central server and assigned randomly to 1 of the 3 netWORK
United Kingdom reading centers (Belfast, Liverpool, and London).
Graders, who were masked to site, participant details, and treat-
ment status, undertook structured grading of the imaging outputs
including angiographic lesion descriptors, area measurements,
tomographic descriptors, and thickness measurements. Final
grading was confirmed by a senior arbitrator (U.C.).
Efficacy Outcome Measures
The coprimary efficacy outcome measures were mean change in
ETDRS BCVA over 12 months and the mean number of PRN
ranibizumab retreatments per participant over 12 months. For the
calculation of the mean number of PRN ranibizumab treatments,
we excluded any treatments administered at the enrollment visit
from the predefined primary outcome because these reflect pre-
existing disease activity, but we included any injections required
at the month 12 visit to provide a total of 12 possible treatments.
Visual secondary efficacy outcomes were the percentage of par-
ticipants losing fewer than 15 ETDRS letters, gaining 0 letters or
more, and gaining 15 letters or more from enrollment to month 12.
Structural secondary efficacy outcomes at month 12 were mean
change in angiographic total lesion size, angiographic CNV size,
and OCT foveal thickness.
Safety Outcomes
Safety outcomes included all adverse events (AEs) and serious
adverse events (SAEs), coded by an independent contractor using
the Medical Dictionary for Regulatory Activities (MedDRA)
preferred terms. One of 2 trial ophthalmologists (T.L.J. and J.E.N.)
resolved queries.
A key safety outcome was the presence of microvascular
abnormalities (MVAs) that may be attributable to radiation. Graders
were trained to identify MVAs of the retinal circulation and reported
their presence and location with respect to the neovascular AMD
lesion (in the retina overlying the lesion or in the retina outside the
lesion). If MVAs were observed at any visit, these were arbitrated by
the senior clinician for each reading center to confirm if they were
present. All cases of MVA were subjected to a final arbitration by
one of the netWORK United Kingdom clinicians (U.C.).
Subgroup Analysis
The CABERNET study suggested several baseline ocular charac-
teristics that may influence the clinical response to EMB.11
Accordingly, the MERLOT statistical analysis plan included a
predefined, exploratory subgroup analysis of the coprimary
outcomes based on baseline lens status (phakic or pseudophakic),
BCVA (53 letters or >53 letters), lesion type (predominantly
classic, minimally classic, or occult), and lesion size (3.5 or
>3.5 optic disc areas).
Statistical Analysis
Unless otherwise specified, continuous variables are summarized
using mean  standard deviation and categorical variables are
summarized using proportions. All analyses used 2-sided tests with
a type I error rate of 0.05. All analyses were prespecified in a
statistical analysis plan. Those analyses that adjust for baseline
lesion type considered the 5 participants whose lesions wereclassified as retinal angiomatous proliferation as having occult
lesions.
Calculation of Sample Size. We expected each group to have a
baseline VA of 65.5 ETDRS letters with a standard deviation of
14.6 letters. We expected 8 injections in the ranibizumab mono-
therapy arm with a standard deviation of 4, and 6 injections in the
EMB arm with a standard deviation of 3. A sample size of 330
participants (220 in the EMB arm and 110 in the ranibizumab
monotherapy arm) would provide 90% power for a 5-letter non-
inferiority margin for VA and more than 90% power to detect a
difference of 2 injections with a 2-sided significance level of 5%.
An additional 10% of participants were added, which gave a final
sample size of 363. The assumptions used in these calculations
are based on the results of the Prospective Optical Coherence
Tomography Imaging of Patients with Neovascular AMD Treated
with Intraocular Ranibizumab study.12,13
Analysis of Coprimary Outcomes. The study was designed to
test the hypothesis that EMB would reduce the frequency of
ranibizumab retreatment that patients require while maintaining
VA. Therefore, the VA coprimary outcome was tested for non-
inferiority of the EMB group to the ranibizumab monotherapy
group, and the ranibizumab retreatment outcome was tested for
superiority. For the noninferiority outcome, a 2-sided test at the
0.05 significance level is equivalent to a 1-sided test at the 0.025
significance level. No adjustment to the type I error rate was made
because rejection of the null hypothesis required both noninferior
VA and fewer retreatment injections in the EMB arm.
We used an analysis of covariance model adjusted for baseline
VA, lens status (phakic or pseudophakic), and lesion type (pre-
dominantly classic, minimally classic, or occult) to test whether the
change in VA in the EMB group was noninferior to the change in
the ranibizumab monotherapy group. To show noninferiority, the
lower bound of the 95% confidence interval of the mean difference
between the groups in change in VA must lie above the pre-
determined noninferiority margin of 5 letters. We used an
analysis of covariance model adjusted for baseline lens status and
lesion type to test whether the 2 groups differed in the frequency of
their ranibizumab use. The analysis used the intention-to-treat
population, comprising all randomized participants regardless of
eligibility (inclusion or exclusion) error, postrandomization with-
drawal, and whether the correct study treatments were received or
other interventions were received.
Analysis of Secondary Efficacy Outcomes. The VA secondary
efficacy outcomes are summarized using proportions. P values are
from stratified Mantel-Haenszel tests adjusting for baseline lens
status and lesion type. The OCT and angiographic secondary
outcomes were summarized using least squares means, standard
deviations were calculated from least squares standard errors
(SE O n), and P values were calculated from analysis of
covariance models of the outcome adjusted for the baseline of the
outcome, lens status, and lesion type.
Missing Data. All analyses of VA included all 363 participants.
We used multiple imputation to impute the month 12 VA mea-
surement for the 13 participants who were missing their month 12
measurement. The ranibizumab retreatment injection analysis also
included all participants. Because these injections may be more
likely to occur toward the early part of the 12-month period before
any potential benefit of radiation manifests, no correction was
made for those participants who withdrew early. At baseline, 8
participants were missing FA data and 8 were missing OCT data.
At month 12, FA images were not available for 26 eyes and OCT
images were not available for 19 eyes. We did not perform any
imputation for these missing data; all analyses based on the
angiographic and OCT data include only participants with both
baseline and month 12 measurements.1289
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Baseline Demographics
Of the 363 participants, 350 (96.4%) completed 12 months of
follow-up. Participant allocation and disposal are shown in Figure 2.
All participants were white. The mean age was 76.97.2 years in the
EMB arm and 75.87.6 years in the ranibizumab monotherapy arm
(combined, 76.57.2 years; range, 56e96 years). There was a
smaller proportion of men in the EMB arm (36% vs. 48%), but
adding gender as a predictor in the models for the coprimary
outcomes did not affect the inference. The 2 arms were well
balanced with respect to baseline ocular characteristics (Table 1).
Overall, the reading center determined the lesion composition at
enrollment to be occult in 75%, minimally classic in 12%,
predominantly classic in 12%, and retinal angiomatous
proliferation in 1%. Those in the EMB arm had received a mean
of 11.65.5 anti-VEGF injections before enrollment, compared
with 10.65.0 injections in the ranibizumab arm.Figure 2. Diagram showing the Consolidated Standards of Reporting Trials (CO
primary outcome. The statistical analysis plan included provision for missing vis
the analysis was greater than those reaching the 12-month end point.
1290Number of Ranibizumab Retreatments
The mean number of PRN ranibizumab injections in the 363 par-
ticipants, from month 1 to 12 inclusive, was 4.83.2 in the EMB
arm (n ¼ 244) and 4.12.4 in the ranibizumab monotherapy arm
(n ¼ 119; Fig 3). Accordingly, the study failed to show superiority
of EMB in terms of fewer injections. The difference between
groups was not statistically significant (P ¼ 0.068). The
percentage of participants by number of injections is shown in
Figure 4 (available at www.aaojournal.org).Visual Acuity
The mean change in BCVA from baseline to month 12
was 4.810.8 letters in the EMB arm (n ¼ 244) and 0.99.7
letters in the ranibizumab monotherapy arm (n ¼ 119; Fig 5). The
95% confidence interval of the difference between groups
was 6.6 to 1.8 letters, and so the study did not demonstrate
noninferiority at the prespecified 5-letter inferiority margin;NSORT) allocation and disposal of study participants up to the 12-month
ual acuity and injection data, hence the number of participants included in
Table 1. Baseline Ocular Characteristics
Epimacular Brachytherapy (n [ 244) Ranibizumab (n [ 119) Total (n [ 363)
Baseline ETDRS letters
No. 244 119 363
Mean (SD) 62.7 (13.7) 64.4 (12.9) 63.2 (13.5)
Range (minimumemaximum) 13e86 34e88 13e88
Quartiles (25th, median, 75th) 53, 66, 73 56, 67, 74 54, 66, 73
Lens status, no. (%)
Phakic 174 (71) 90 (76) 264 (73)
Pseudophakic 70 (29) 29 (24) 99 (27)
Lesion type, no. (%)
Occult with no classic 180 (74) 91 (76) 271 (75)
Minimally classic 31 (13) 13 (11) 44 (12)
Predominantly classic 30 (12) 13 (11) 43 (12)
RAP 3 (1) 2 (2) 5 (1)
Total lesion size (mm2)
No. 240 115 355
Mean (SD) 9.1 (7.7) 9.8 (7.0) 9.3 (7.5)
Range (minimumemaximum) 0e45 0e43 0e45
Quartiles (25th, median, 75th) 4, 7, 12 4, 8, 14 4, 7, 13
Total lesion size category (DA), no. (%)
3.5 143 (60) 61 (53) 204 (57)
>3.5 97 (40) 54 (47) 151 (43)
Total CNV size (mm2)
No. 240 115 355
Mean (SD) 5.7 (7.4) 5.7 (6.3) 5.7 (7.0)
Range (minimumemaximum) 0e45 0e43 0e45
Quartiles (25th, median, 75th) 0, 4, 8 1, 4, 9 0, 4, 9
Foveal thickness (mm)
No. 238 117 355
Mean (SD) 378.0 (189.3) 415.0 (396.0) 390.2 (275.1)
Range (minimumemaximum) 60e1776 119e3996 60e3996
Quartiles (25th, median, 75th) 256, 344, 445 252, 338, 452 254, 341, 448
Anti-VEGF injections before enrollment
No. 244 119 363
Mean (SD) 11.6 (5.5) 10.6 (5.0) 11.3 (5.4)
Range (minimumemaximum) 5e36 5e30 5e36
Quartiles (25th, median, 75th) 7, 10, 15 7, 9, 13.2 7, 10, 14
CNV ¼ choroidal neovascularization; DA ¼ disc area; ETDRS ¼ Early Treatment Diabetic Retinopathy Study; RAP ¼ retinal angiomatous proliferation;
SD ¼ standard deviation; VEGF ¼ vascular endothelial growth factor.
Jackson et al  MERLOT Study of Epimacular Brachytherapyrather, it showed significantly better BCVA in the ranibizumab
monotherapy group. The secondary visual outcomes are shown in
Table 2 (available at www.aaojournal.org).
Optical Coherence Tomography
Of 363 participants, 336 (93%) completed both baseline and month
12 OCT examinations. The mean foveal thickness reduced mini-
mally by 1.0215 mm in the EMB arm (n ¼ 225) and
by 15.7196 mm in the ranibizumab monotherapy arm (n ¼ 111;
P ¼ 0.43).
Fluorescein Angiography
In the 329 of 363 participants (91%) with completed baseline and
12-month FA results, the total lesion size increased by 1.28.3
mm2 in the EMB arm (n ¼ 219) and by 0.47.6 mm2 in the
ranibizumab monotherapy arm (n ¼ 110; P ¼ 0.27). The CNV size
decreased by 0.57.6 mm2 in the EMB arm and by 1.37.0 mm2
in the ranibizumab arm (P ¼ 0.27).Safety
Table 3 (available at www.aaojournal.org) shows the AEs that
occurred in the study eye. More AEs occurred in eyes in the
EMB arm than in eyes in the control arm. The most common
ocular AE was visually significant cataract requiring surgical
intervention, which occurred in 33.6% of eyes treated with EMB
versus 9.2% of eyes in the control arm, followed by reduced VA
(16.0% vs. 6.7%, respectively) and eye pain (7.8% vs. 4.2%).
Most other ocular AEs were uncommon.
Table 4 (available at www.aaojournal.org) shows all AEs,
excluding those in the study eye. There was a similar proportion
of nonocular AEs in both group.
The SAEs in the study eye, and their relatedness to treatment,
are shown in Table 5. The most clinically serious event was 1
case of endophthalmitis. The participant underwent EMB with
cataract surgery 6 months later. Four weeks after cataract
surgery culture-positive Streptococcus pneumoniae endoph-
thalmitis developed, leading to rapid corneal perforation and
subsequent evisceration. Two other patients initially were1291
Figure 3. Box-and-whisker plot showing the number of pro re nata rani-
bizumab injections given up to and including month 12, but excluding any
injections given at enrollment because of pre-existing disease activity. The
top and bottom of the box show the third and first quartiles, respectively,
with the median shown as the band inside the box. The top and bottom
error bar show the highest observation still within 1.5 times the inter-
quartile range (IQR) of the upper quartile, and the lowest observation still
within 1.5 IQR of the lower quartile. Outliers are shown as unfilled circles.
The mean is shown as a filled square inside the box.
Figure 5. Box-and-whisker plot showing the change in Early Treatment of
Diabetic Retinopathy Study (ETDRS) visual acuity (VA) at 12 months
after enrollment, comparing the epimacular brachytherapy group with the
ranibizumab monotherapy group. Figure conventions are the same as
detailed in the legend to Figure 3. Extreme outliers (those more than 3 IQR
above the upper quartile or below the lower quartile) are shown as filled
circles.
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investigators subsequently changed the diagnosis to severe post-
operative uveitis. One of these patients sought treatment 2 days
after EMB with hypopyon and reduced vision, and therefore was
treated with intravitreal antibiotics. There was a light growth of
Staphylococcus epidermidis in the vitreous sample, but the mi-
crobiologists considered this to be a contaminant. The BCVA in
this participant was 49 letters at baseline and 28 letters at month
12. In the second patient, 3 days after EMB, a hypopyon with
reduced vision developed, and the patient was treated with
intravitreal antibiotics. Aqueous and vitreous culture results were
negative, and a full visual recovery occurred with no lasting
sequelae (BCVA was 41 letters at baseline and 46 letters at month
12). Three retinal detachments occurred in the EMB group.
Table 6 (available at www.aaojournal.org) shows all SAEs,
excluding those in the study eye. A total of 202 SAEs occurred
in the EMB group and 93 in the control group.
The reading center inspection for radiation damage found 1.1%
(4/350) of study eyes had an MVA at baseline, all of which were in
the EMB arm. There were no MVAs in fellow eyes. At month 12,
1.4% (5/350) of study eyes had MVAs, all of which occurred in the
EMB arm. Table 7 (available at www.aaojournal.org) shows the
types of MVAs. In 1 of the 5 patients with an MVA, the month
12 analysis revealed a new tortuous or dilated vessel with
capillary nonperfusion that was not present at baseline (Fig 6).
This was attributed to radiation damage, and the BCVA in this
patient dropped from 54 ETDRS letters at baseline to 35 letters
at month 12. In the other 4 patients, the same MVAs occurred at1292baseline as month 12, and the reading center determined that
these were not radiation damage.
Subgroup Analysis
Figure 7 (available at www.aaojournal.org) shows that most
subgroups favored the ranibizumab monotherapy group in terms
of the mean number of PRN ranibizumab injections, but the
baseline characteristics associated with a smaller difference
between groups were phakic lens, VA better than 53 letters,
classic lesions, and small lesions (3.5 disc areas or less). The
subgroup analysis of VA also tended to favor the ranibizumab
group, but the baseline ocular characteristics associated with a
smaller difference between groups were phakic lens, VA of 53
letters or worse, occult lesions, and small lesions (Fig 8,
available at www.aaojournal.org). Although some baseline
characteristics were associated with a better response to EMB,
none of the EMB subgroups showed noninferiority of VA or
significantly fewer injections than the ranibizumab monotherapy
arm.
Discussion
This study tested the safety and efficacy of EMB for patients
with chronic, active neovascular AMD already receiving
ranibizumab monotherapy. On the basis of phase 2 data, we
hypothesized that EMB would reduce the number of
Table 5. Ocular Serious Adverse Events in the Study Eye and Relatedness to Treatment
Eye Disorders Events % Intensity
Epimacular
Brachytherapy Vitrectomy Ranibizumab
Intravitreal
Injection
Epimacular brachytherapy (n ¼ 244)
Visual acuity reduced 4 1.6 Severe Possibly Possibly Unlikely Possibly
Severe Possibly Likely Unlikely Unlikely
Severe Unlikely Unlikely Unlikely Unlikely
Moderate Not related Not related Possibly Likely
Vitreous hemorrhage 1 0.4 Moderate Not related Not related Possibly Likely
Retinal hemorrhage 3 1.2 Severe Unlikely Unlikely Unlikely Unlikely
Moderate Unlikely Unlikely Unlikely Unlikely
Severe Unlikely Unlikely Unlikely Unlikely
Retinal detachment 3 1.2 Severe Possibly Possibly Possibly Possibly
Moderate Not related Definitely Not related Not related
Severe Unlikely Likely Possibly Possibly
Vision blurred 1 0.4 Severe Possibly Possibly Possibly Possibly
Endophthalmitis 1 0.4 Severe Not related Possibly Not related Not related
Vitreous floaters 1 0.4 Severe Possibly Possibly Unlikely Possibly
Postoperative uveitis 2 0.8 Severe Possibly Likely Unlikely Unlikely
Severe Possibly Possibly Unlikely Possibly
Ranibizumab monotherapy (n ¼ 119)
Visual acuity reduced 1 0.8 Moderate N/A N/A Unlikely Unlikely
Retinal hemorrhage 1 0.8 Moderate N/A N/A Unlikely Unlikely
N/A ¼ not applicable.
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maintain a noninferior VA. The results do not support either
hypothesis. Indeed, at 12 months those who underwent
EMB averaged more injections (albeit not significantly
more) and had VA that was significantly worse than those
who continued with ranibizumab monotherapy. Therefore,
the results of this study do not support the use of EMB in
previously treated patients with neovascular AMD.
The current results differ from the phase 2 MERITAGE
study of EMB, which suggested that EMB reduces the
frequency of anti-VEGF retreatment in chronic, active neo-
vascular AMD.9,10 The MERITAGE study recruited a very
similar patient population and used the same EMB device,
dose, and technique.9 Retreatment criteria also were similar.
The MERITAGE study found that the anti-VEGF injection
rate reduced by one-third comparing treatment before and
after EMB, but there was no control group. Of 53 partici-
pants, 81% lost fewer than 15 ETDRS letters, which is
similar to the current result (84%) and not dissimilar to the
natural history of chronic AMD, which is often characterized
by reducing VA after the initial improvement at the start of
anti-VEGF treatment.14,15 By contrast, the control group in
MERLOT showed a very stable VA, with 92% losing fewer
than 15 letters and a mean loss of only 0.9 letters over 12
months. Therefore, the current EMB VA results are similar
to the phase 2 study, but the control group displayed better
than expected vision. By contrast, the expected reduction in
injection frequency seen in MERITAGE was not evident in
MERLOT, relative to the control group. The reason for these
differences are speculative, but may relate to surgical tech-
nique, clinician experience and training, case selection,
chance, or some other unidentified factor or factors.
The VA results seem similar to those of the CABERNET
study, a large randomized controlled trial of EMB intreatment-naïve disease.6,7 That study also failed to establish
noninferiority of VA using a similar noninferiority margin
of 10%. However, because the CABERNET control group
received a more intensive, mandated injection regimen, it
was difficult to isolate the beneficial or deleterious effect of
EMB. Furthermore, CABERNET was not designed to
establish whether EMB reduced the need for anti-VEGF
therapy, although participants in the EMB arm received
relatively few injections (an average of 6.2 over the 2-year
study).6 It is possible that the VA results in the
CABERNET EMB arm were the result of undertreatment;
however, this was not the case in MERLOT, where the
radiotherapy arm showed a trend for worse VA than the
control arm, despite receiving more injections.
The results of this study are in contrast with those of the
IRay in Conjunction with Anti-VEGF Treatment for Pa-
tients with Wet AMD (INTREPID) study.16 The INTREPID
study met its primary end point, showing a statistically
significant reduction in anti-VEGF therapy after radio-
therapy. It had a similar study design, enrolling participants
with previously treated neovascular AMD who then were
randomized to combined radiotherapy and anti-VEGF
therapy or to anti-VEGF monotherapy. The dose of radio-
therapy also was similar comparing INTREPID and
MERLOT. The main difference lay in radiotherapy delivery,
with INTREPID using teletherapy and MERLOT using
intraocular brachytherapy. Thus, INTREPID avoided the
effects of vitrectomy.
There are several possible explanations for the very
different results between EMB and stereotactic teletherapy.
First, EMB requires manual positioning of the probe over the
area of greatest disease activity. For occult lesions (75% of
those in the present study), it can be hard to define the area
of greatest activity. This risk is amplified by the short range1293
Figure 6. Fundus photographs and angiograms of the participant in whom retinal microvascular abnormality secondary to epimacular brachytherapy
developed: baseline (A) fundus photograph and (B) fundus fluorescein angiogram, (C) month 12 fundus photograph showing a new tortuous and dilated
vessel (black arrow), and (D) month 12 angiogram showing capillary dropout adjacent to the abnormal vessel.
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fact that surgeons may hold the probe away from the
retinal surface to reduce the risk of trauma. Vitrectomy is
known to cause cataract, whereas stereotactic radiotherapy
was not noted to do so.16 Vitrectomy also reduces
intravitreal drug half-life,17e19 so if there is any residual
disease activity, this may be harder to control or it may
require more frequent injections to maintain a therapeutic
effect.
More AEs and SAEs occurred in EMB-treated eyes,
including a higher rate of cataract. Radiation has the
potential to induce cataract, but the dose received by the lens
during EMB is approximately one thousandth of that
thought to cause lens opacity.20 By contrast, vitrectomy is
well known to cause cataract in most phakic eyes.21 It
seems likely, then, that the higher rate of cataract was
caused by vitrectomy rather than by EMB. More cases of
retinal detachment and endophthalmitis occurred in the
EMB-treated eyes, but this was also true of the fellow
eye, and with very low numbers of events, these may have
occurred by chance. The SAEs in the study were not usually
attributed to EMB, and the severe endophthalmitis case
occurred 7 months after EMB, but only 1 month after
cataract surgery, suggesting the latter may have been
responsible. The other organ classes with higher than
expected AEs and SAEs did not point to any expected or
theoretical risk, such as neoplasia secondary to radiation
exposure, although such a risk cannot be excluded. The rate1294of arteriothrombotic events was lower in the EMB arm,
despite receiving more ranibizumab injections.
Fundus photographs, FA images, and OCT images
analyzed by an independent reading center failed to show
any benefit from EMB. Although not significantly different,
all the predefined structural outcomes favored the control
group, including change in angiographic lesion size, CNV
size, and OCT thickness.
The subgroup analysis was designed to help refine case
selection if EMB was shown to be effective or to identify
subsets of patients for whom EMB may be effective if the
group as a whole did not show benefit, subject to confir-
matory studies. Unfortunately, we failed to identify partic-
ipants who did significantly better than ranibizumab
monotherapy, and our results do not seem to justify further
studies.
Strengths of the MERLOT study include its size, ran-
domized controlled design, and independent reading center
evaluation of structural outcomes. It was not possible to
mask the study fully because there is no feasible way to
mimic vitrectomy. This may have had relatively little effect
on VA assessment, which was carried out according to a
strict protocol by masked assessors. Bias may be more likely
to influence AE reporting and retreatment decisions, but the
retreatment criteria were well defined and the key parame-
ters driving retreatment decisions were masked (BCVA) or
automated (OCT). Furthermore, we would have anticipated
fewer injections assuming clinicians may be more inclined
Jackson et al  MERLOT Study of Epimacular Brachytherapynot to inject EMB-treated eyes if they expected EMB to
reduce the injection frequency, and injecting may be
perceived as a treatment failure. We cannot exclude con-
founding resulting from cataract occurring after vitrectomy,
which could improve the perceived benefit of EMB falsely if
pre-existing lens opacity was removed subsequently or
could reduce VA if developing cataract did not yet warrant
removal. However, our predefined subgroup analysis in
pseudophakic eyes also showed VA favoring ranibizumab
monotherapy.
In summary, this study does not support the use of EMB
for previously treated neovascular AMD. Indeed, the VA
results suggest vision may be worse than with ranibizumab
monotherapy, and there was a trend for worse structural
outcomes. We did not identify any subgroup of patients who
respond well to EMB or who warrant further study. Three
years of safety follow-up is planned because radiation reti-
nopathy can occur beyond the current 12-month milestone.
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